Targeting BCL-2 as a Therapeutic Strategy for Primary p210BCR-ABL1-positive B-ALL Cells

Conclusion: BCL-2 is a key survival factor for primary Ph+ B-ALL cells and its inhibition - alone or in combination with a BCR-ABL1 TKI - should be further investigated as a potential therapeutic strategy for these patients.

Source: In Vivo - February 27, 2020 Category: Research Authors: MASSIMINO, M., TIRRO, E., STELLA, S., PENNISI, M. S., VITALE, S. R., PUMA, A., ROMANO, C., DI GREGORIO, S., ROMEO, M. A., DI RAIMONDO, F., MANZELLA, L. Tags: Experimental Studies Source Type: research